Topical Isotretinoin vs Tretinoin for Acne

Topical isotretinoin vs tretinoin has no clear winner for acne. Two old direct trials found similar improvement over 12 weeks, and neither proved one drug superior. Tretinoin is the practical option when your prescriber is choosing a current licensed topical. Topical isotretinoin only enters the decision where a licensed local product still exists. In the UK, none is currently listed. A prescriber should choose based on the licensed product, its vehicle, your acne and your tolerance.

They are related, but they are not the same drug

Topical isotretinoin is 13-cis-retinoic acid. The acne trials used a 0.05% gel placed on the skin. Tretinoin is all-trans-retinoic acid. Current products include creams, gels and lotions, depending on the country.

Both are topical retinoids. They change how cells shed inside the hair follicle, which helps prevent clogged pores. A matching percentage does not mean matching potency. The molecule and the base both affect delivery and irritation.

Topical isotretinoin is also not Accutane treatment. Accutane is a familiar brand name for oral isotretinoin capsules. Oral isotretinoin reaches the whole body and has separate indications, monitoring and pregnancy controls. Tretinoin is a third, distinct drug.

Topical isotretinoin and tretinoin for acne

Decision point	Topical isotretinoin	Topical tretinoin
Direct comparison	Two older 12-week trials found no clear efficacy advantage over tretinoin	The same trials found no clear efficacy advantage over topical isotretinoin
Forms tested head to head	0.05% gel	0.05% preparation or cream
Current verified availability	No topical product appears in the UK eMC isotretinoin list, checked 11 November 2026	US prescription creams and gels are current. The UK has prescription combination products
Time assessed	Benefits emerged across 5 to 12 weeks in old trials	The US cream label says a definite benefit may take more than 6 weeks
Common drawback	Dryness, redness, stinging and peeling can occur	Dryness, redness, stinging and peeling can occur
Pregnancy	UK regulators contraindicate topical retinoids during pregnancy and pregnancy planning	The same UK warning covers topical tretinoin

What did the head-to-head trials find?

A direct comparison does exist. David Elbaum reported a double-blind, 12-week trial in the Journal of the American Academy of Dermatology in 1988. People with moderate acne used 0.05% topical isotretinoin or 0.05% topical tretinoin. Both groups had fewer papules and pustules. Neither preparation was statistically superior.

That result does not prove the drugs are equal. The abstract does not report the group sizes, and the study is almost four decades old. Its formulations may not match a product sold today.

Judith Domínguez and colleagues ran a second direct trial in Mexico City. Their 1998 International Journal of Dermatology paper included only 30 people aged 13 to 30. Fifteen received isotretinoin 0.05% gel, while 15 received tretinoin 0.05% cream.

After 12 weeks, both groups improved in inflammatory and non-inflammatory lesions. Seven isotretinoin participants reported mild irritation. Ten tretinoin participants reported stinging, with redness and peeling later in treatment. With 15 people per group, that gap is too imprecise to establish a tolerability advantage.

Topical isotretinoin also beat its vehicle in a larger controlled trial. Chalker and colleagues studied 268 completers with mild to moderate acne in 1987. The 0.05% gel separated from vehicle for inflammatory lesions after five weeks. It separated for non-inflammatory lesions and overall severity after eight weeks. This shows activity, not superiority to tretinoin.

Why tretinoin is usually the practical comparison winner

The evidence does not make tretinoin the stronger molecule. Availability does. Current US DailyMed labels list prescription tretinoin cream at 0.025%, 0.05% and 0.1%. They also list prescription gel at 0.01% and 0.025%.

The UK picture is different. The electronic Medicines Compendium currently lists isotretinoin capsules, not a topical isotretinoin product. Its current Treclin label contains 0.025% tretinoin with 1% clindamycin and classifies it as prescription-only. That combination is not interchangeable with plain tretinoin because it also contains an antibiotic.

Guidelines follow current treatment choices. Reynolds and colleagues' 2024 American Academy of Dermatology guideline strongly recommends topical retinoids as a class. It does not say topical isotretinoin beats tretinoin. Updated NICE guidance names fixed tretinoin-clindamycin as one UK first-line option and reviews first-line treatment at 12 weeks.

Availability varies by country. If a seller offers topical isotretinoin, check the national product label and prescription status with a pharmacist. An old trial does not confirm that an online product is licensed, genuine or equivalent.

Expect weeks, not overnight clearing

The useful review window is about 8 to 12 weeks. That fits the direct trials, the vehicle-controlled isotretinoin trial and current NICE guidance. Early dryness or a temporary flare can appear before a clear benefit. More product does not make a retinoid work faster.

The cleanest way to judge progress is to keep the rest of the routine steady. Use a gentle cleanser, a plain non-comedogenic moisturiser and sunscreen. Avoid adding scrubs, peels or several drying acne products without asking the prescriber. Those changes can cause irritation that looks like treatment failure.

NICE says clinicians can consider alternate-day or short-contact use at first to reduce irritation. That is a plan to discuss, not a reason to change a prescription yourself. Ask what to do if redness, swelling, blistering or crusting becomes marked.

For a broader benchmark, see how long acne treatments take to work. If tretinoin is the available choice, the separate tretinoin strength comparison explains why a larger percentage is not automatically better.

Pregnancy warnings apply to both topical retinoids

The UK MHRA says systemic exposure from topical retinoids is thought to be negligible. It still contraindicates them during pregnancy because fetal risk cannot be excluded. The warning covers both topical isotretinoin and tretinoin, and it also covers pregnancy planning.

US labels use product-specific wording, so the exact advice differs by formulation. Tell the prescriber if pregnancy is possible or planned. If exposure has already happened, contact the prescriber promptly for advice rather than drawing conclusions from oral isotretinoin warnings.

Do not confuse either topical with oral isotretinoin

Oral isotretinoin is not a stronger tube of the same treatment. The 2024 AAD guideline recommends it for severe acne, scarring or major psychological burden, or acne that has failed standard therapy. It needs clinician supervision and carries strict pregnancy safeguards.

If you have deep painful nodules, new scars or widespread acne, a topical-only comparison may be the wrong decision. Read when dermatologists consider oral isotretinoin, then discuss the options with a clinician. Do not use capsule evidence to estimate what a topical gel will do.

How to make the decision

First, identify the exact medicine: isotretinoin or tretinoin, topical or oral, strength, vehicle and country label. Similar names are not enough. Then ask whether the product is licensed for acne where you live and whether it contains another active ingredient.

If licensed topical isotretinoin is available and a prescriber offers it, the old trials do not show that it clears acne better than tretinoin. If tretinoin is the current licensed option, its advantage is practical availability and stronger support in current treatment pathways, not a proven head-to-head efficacy win.

A clinician should make the call when acne is deep, painful, scarring, infected or affecting your mental health. Get a review if an adequate prescribed course has not helped by the planned assessment. The guide to cystic acne and dermatologist care explains why deep lesions need a different threshold for help.